Evidence map›Paper›PMID 32434884›Full record

Trial reportJournal of virology2020

HIV RNA Rebound in Seminal Plasma after Antiretroviral Treatment Interruption.

Sara Gianella, Antoine Chaillon, Tae-Wook Chun, Michael C Sneller, Caroline Ignacio, Milenka V Vargas-Meneses, Gemma Caballero, Ronald J Ellis, Colin Kovacs, Erika Benko and 2 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01859325 (A Phase I Randomized, Double-Blind, Placebo-Controlled Study of a Multi-Antigen DNA Vaccine Prime Delivered by In Vivo Electroporation, rVSV Booster Vaccine in HIV-Infected Patients Who Began Antiretroviral Therapy During Acute/Early Infection), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01859325 phase1completednot on this map

A Phase I Randomized, Double-Blind, Placebo-Controlled Study of a Multi-Antigen DNA Vaccine Prime Delivered by In Vivo Electroporation, rVSV Booster Vaccine in HIV-Infected Patients Who Began Antiretroviral Therapy During Acute/Early Infection

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2013 to 2017Enrolled33ConditionsHIV, Therapeutic VaccineArmsrVSV, IL-12 pDNA adjuvant, HIV-Mag pDNA, Placebo
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Sara Gianella *University of California, San Diego, La Jolla, California, USA gianella@ucsd.edu.
Antoine Chaillon *University of California, San Diego, La Jolla, California, USA.ORCID 0000-0001-9490-3857
Tae-Wook ChunNational Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Michael C SnellerNational Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Caroline IgnacioUniversity of California, San Diego, La Jolla, California, USA.
Milenka V Vargas-MenesesUniversity of California, San Diego, La Jolla, California, USA.
Gemma CaballeroUniversity of California, San Diego, La Jolla, California, USA.
Ronald J EllisUniversity of California, San Diego, La Jolla, California, USA.
Colin KovacsMaple Leaf Medical Clinic, Toronto, Ontario, Canada.
Erika BenkoMaple Leaf Medical Clinic, Toronto, Ontario, Canada.
Sanja HuibnerDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada.
Rupert KaulDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada.
University of California San Diego · USUniversity of Toronto · CANational Institutes of Health · USMaple Leaf Medical Clinic · CA

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jennifer E Iudicello · 2001 to 2026
$50.4M
Role of Viral Reservoirs in the Pathogenesis of HIV DiseaseZIAAI000851 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHUN, TAE-WOOK · 2009 to 2025
$29.3M
Revealing Reservoirs during Rebound (R3)P01AI131385 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WEIBEL, NADIR · 2017 to 2021
$8.7M
Age related determinants of HAND: A 12 year follow-up of CHARTER participantsR01MH107345 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HEATON, ROBERT KERNACHAN, LETENDRE, SCOTT L · 2015 to 2021
$7.9M
Perturbing the HIV Reservoir with Immune StimulationR01AI118422 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SMITH, DAVID MITCHELL · 2016 to 2020
$3.8M
Mechanisms of CMV Replication on HIV PersistenceR01AI147821 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GIANELLA WEIBEL, SARA · 2020 to 2024
$3.2M
The HIV-associated Opioid Micro-Environment (HOME) ProjectDP2DA051915 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GIANELLA WEIBEL, SARA · 2020 to 2020
$2.4M
Effect of Declining Sex Hormones on HIV persistence in HIV Infected Women on ARTR21HD094646 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GIANELLA WEIBEL, SARA · 2017 to 2018
$441k
The Prostate as a Reservoir for Residual ReplicationR21AI131971 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHAILLON, ANTOINE · 2018 to 2019
$432k
Effect of Sex Hormones on HIV persistenceR21AI134295 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GIANELLA WEIBEL, SARA · 2017 to 2018
$426k
NCATS NIH HHS UL1 TR001442NIAID NIH HHS P01 AI131385NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI118422NIAID NIH HHS R01 AI147821NIAID NIH HHS R21 AI131971NIAID NIH HHS R21 AI134295NICHD NIH HHS R21 HD094646NIDA NIH HHS DP2 DA051915NIMH NIH HHS P30 MH062512NIMH NIH HHS R01 MH107345
6 · The paper itself

Abstract

If strategies currently in development succeed in eradicating HIV reservoirs in peripheral blood and lymphoid tissues, residual sources of virus may remain in anatomic compartments. Paired blood and semen samples were collected from 12 individuals enrolled in a randomized, double-blind, placebo-controlled therapeutic vaccine clinical trial in people with HIV (PWH) who began antiretroviral therapy (ART) during acute or early infection (ClinicalTrials registration no. NCT01859325). After the week 56 visit (postintervention), all participants interrupted ART. At the first available time points after viral rebound, we sequenced HIV-1

Indexed as

HIV InfectionsAdultAnti-Retroviral AgentsDouble-Blind MethodHIV-1HumansMaleMiddle AgedRNA, ViralSemenAnti-Retroviral AgentsRNA, ViralART interruptionseminal plasma

Identifiers

PMID32434884
PMCPMC7375368
OpenAlexW3026337320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.